Inari Medical (NARI)
(Delayed Data from NSDQ)
$49.95 USD
+2.51 (5.29%)
Updated May 24, 2024 03:59 PM ET
After-Market: $49.96 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NARI 49.95 +2.51(5.29%)
Will NARI be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for NARI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NARI
Here's Why You Should Retain Inari Medical (NARI) for Now
Inari Medical (NARI) Q1 Earnings Miss Estimates, OpEx Rises
NARI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inari Medical, Inc. (NARI) Reports Q1 Loss, Tops Revenue Estimates
What's in Store for These 5 Medical Device Stocks in Q1 Earnings?
Why You Should Retain Inari Medical (NARI) Stock for Now
Other News for NARI
Inari Medical Files Patent Infringement Lawsuit Against Imperative Care and Truvic Medical
Inari Medical files patent infringement lawsuit against Imperative Care, Truvic
Insider Sale: Director William Hoffman Sells 40,000 Shares of Inari Medical Inc (NARI)
Grant & Eisenhofer Files Class Action Lawsuit Against Inari Medical, Inc. on Behalf of Institutional Investor
Inari Medical: A Strong Buy on Growth and Market Expansion Potential